TMDX

NEUTRALEarnings

TransMedics Group, Inc.

2026-02-24

Price

$137.78

+2.32%

Score6.0Priority

Signals3/8 DNA4/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.6xvs 20d avg

Analysis

TMDX is staging a high-conviction decoupling from the 'Risk-Off' macro regime, driven by a massive Q4 earnings beat (EPS $2.62 vs. $0.41 est) released today. While the broader market liquidates on geopolitical fear (Iran headlines) and the 'AI Fear' contagion from Anthropic, TMDX's 'Perfect Stack' and 1.6x volume surge confirm Institutional Absorption of the stock. The divergence is stark: while Tech and Credit reprice risk, TMDX is being bid up as a tangible growth asset, validated by the recent FDA approval for its ENHANCE Heart trial.

Fired Signals

GOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKQUIET ACCUMULATIONSMA BOUNCEMOMENTUM SHIFTINSIDE OUT

Key Takeaways

**Earnings Super-Beat:** Q4 EPS of $2.62 crushed the $0.41 consensus, proving the OCS platform's operating leverage is inflecting faster than modeled.
**Regulatory De-Risking:** Full FDA approval for the ENHANCE Heart trial (Feb 9) provides a structural tailwind that complements today's financial catalyst.
**Regime Decoupling:** The stock is ignoring the VIX 21.0 spike; the 'Quiet Accumulation' signal suggests funds are rotating out of speculative AI tech into this proven MedTech winner.

← Back to 2026-02-24 View Full TMDX History →Yahoo Finance &nearr;